Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYU688 in Patients With Dengue Fever
NCT06006559Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2024
- Primary completion
- Jul 2027
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in dengue fever comparing EYU688 with Placebo (2 arms). Primary endpoint: Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours. Started Feb 2024; status: recruiting.
02
Drugs
EYU688
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06006559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006559.